Fig. 3From: Gentulizumab, a novel anti-CD47 antibody with potent antitumor activity and demonstrates a favorable safety profileSafety evaluation results of GenSci059. A GenSci059 and the binding test results of different blood groups of red blood cells; B Four concentrations of GenSci059 were combined with human PBMCs; C GenSci059 binds to human platelets; D ADCC and CDC effects of GenSci059Back to article page